Key result
Levosimendan is a novel cardioprotective inotrope that improves haemodynamic performance and potentially improves survival in patients with decompensated heart failure and myocardial ischaemia.
Why the study?
Does levosimendan provide cardioprotection and improve outcomes in patients with decompensated heart failure, myocardial ischaemia, or during surgery?
Population
Patients with decompensated heart failure and myocardial ischaemia, and patients undergoing surgery
Design
Review
Authors
Loading...
May support levosimendan use in select decompensated HF cases; leaves open routine adoption pending RCTs.
Does levosimendan provide cardioprotection and improve outcomes in patients with decompensated heart failure, myocardial ischaemia, or during surgery?
Levosimendan is a novel inotrope that may offer cardioprotective benefits during surgery and in decompensated heart failure by sensitising myofilaments to calcium and activating ATP-dependent potassium channels.
Soeding et al. (2007) conducted a review in Decompensated heart failure and myocardial ischaemia. Levosimendan was evaluated. Levosimendan is a novel cardioprotective inotrope that improves haemodynamic performance and potentially improves survival in patients with decompensated heart failure and myocardial ischaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: